Vulnerability in Oracle Life Sciences Central Designer

CVE-2026-21923

Vulnerability in the Oracle Life Sciences Central Designer product of Oracle Health Sciences Applications (component: Platform). The supported version that is affected is 7.0.1.0. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Life Sciences Central Designer. Successful attacks of this vulnerability can result in unauthorized update, insert or delete access to some of Oracle Life Sciences Central Designer accessible data as well as unauthorized read access to a subset of Oracle Life Sciences Central Designer accessible data. CVSS 3.1 Base Score 6.5 (Confidentiality and Integrity impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N).

Published · last modified .

CVSS v3 metric

CVSS v3 base score 6.5 (Medium). Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N.

EPSS exploit prediction

EPSS: 0.003 (15.9th percentile), scored .

Very low probability of exploitation in the next 30 days; routine patching cadence is appropriate. 16th percentile — 15.9% of CVEs in the catalogue have a lower EPSS than this one. How to read EPSS.

EPSS trend (30 days)EPSS over the last 30 days for CVE-2026-21923: held from 0.002 to 0.003.

EPSS over last 30 days · oldest: 0.002 · newest: 0.003 · change: +0.000

Affected products

References

Frequently asked questions

What is CVE-2026-21923?
CVE-2026-21923 is a medium-severity vulnerability in Oracle Life Sciences Central Designer. CVSS score: 6.5/10. Published 2026-01-20.
How severe is CVE-2026-21923?
Medium severity. CVSS v3 base score is 6.5 out of 10.